PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from Korea

Selling into Europe as a biologics and biosimilars maker from Korea

Your sales team sells biosimilars in Europe without waiting for regulatory affairs.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Korea, Biologics and biosimilarswho it is written for

Why this training matters

Your sales representative sits across from a hospital pharmacist in Germany. She asks how substitution works in her country and what the tender rules mean for your price. He promises to check with Seoul, and by the time the answer comes back, the tender is closed.

What changes after this course

Your team answers those questions in the room, because they know how the European Medicines Agency, national authorities and payers divide the work. You hold a certificate per learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

A buyer asks when your biosimilar can be sold, and your representative answers on the spot. The reply rests on the centralised procedure, the opinion of the Committee for Medicinal Products for Human Use, the European Public Assessment Report and the ten-year market protection that Directive 2001/83/EC gives the reference product. Regulatory affairs hears about it afterwards, not before.

Pricing managers walk into a Paris meeting knowing who decides what. They know the Haute Autorité de Santé assesses the product and the Comité économique des produits de santé negotiates the price. They cite the Transparency Directive 89/105/EEC when a payer stalls, and they stop treating European Commission authorisation as if it settled the price.

Marketing drafts a leaflet that matches the summary of product characteristics, as Directive 2001/83/EC requires, and checks it against the German Heilmittelwerbegesetz and the European Federation of Pharmaceutical Industries and Associations Code of Practice before legal sees it. Medical science liaisons know a written contract and a documented need come before the first paid meeting. Nobody guesses whether a dinner is hospitality or a gift.

The supply chain lead hands an inspector a temperature excursion procedure written to the Good Distribution Practice guidelines, and the importer's Qualified Person finds every record needed to certify a batch. Safety staff log a serious reaction in EudraVigilance within 15 days of the day any employee heard of it, with brand name and batch number attached.

Who needs this training

  • Head of International Sales

    When a hospital buyer asks who sets the price and whether pharmacists may substitute, this person answers in the room and the tender stays alive.

  • Regulatory Affairs Manager

    Marketing sends a leaflet for review, and this person checks each claim against the summary of product characteristics and the advertising rules of Directive 2001/83/EC, so the problem is found before a national authority finds it.

  • Supply Chain Lead

    An inspector asks for the temperature record of a shipment handed between carrier, warehouse and wholesaler. This person produces it for each handover under Good Distribution Practice.

  • Medical Science Liaison

    A professor asks for a talk, a trip and a fee in one email. This person knows which part the contract and the European Federation Code of Practice permit, and which part to decline.

  • Pharmacovigilance Officer

    A sales representative mentions a patient reaction at the end of a visit. This person knows the 15-day clock has started and what the report in EudraVigilance must carry.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: Korea

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Name the French body that assesses a product and the one that negotiates its price.
  2. Check a leaflet claim against the summary of product characteristics and mark any line that the advertising rules of Directive 2001/83/EC would reject.
  3. Decide whether a gift, meal or sponsorship passes the European Federation of Pharmaceutical Industries and Associations Code of Practice, and record the reasoning.
  4. Write a temperature excursion procedure that follows the Good Distribution Practice guidelines and hand it to an inspector.
  5. Start the 15-day reporting clock correctly for a serious adverse reaction and enter the report in EudraVigilance with brand name and batch number.
  6. Explain to a doctor what the 2022 European statement on interchangeability says and where national substitution rules take over.
  7. List the parties that must be based in the European Economic Area before the first sale, including the marketing authorisation holder.

What the company gets

  • Your market entry plan names the marketing authorisation holder, importer, Qualified Person and pharmacovigilance lead before the first order, so no filing waits on a missing role.
  • Sales representatives stop promising to check with head office, because the common questions on pricing, substitution and authorisation status already have answers.
  • Leaflets and slides reach legal already matched to the summary of product characteristics, which shortens the review queue and leaves fewer withdrawn pieces.
  • An inspector asking about cold chain or safety reporting gets a written procedure and a training record for each person who carries it out.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Size up the European biologics and biosimilars market before you commit

    • How to pick your first European countries for a biosimilar and defend the choice to your board.
    • Why the ten-year market protection on a reference biologic sets the earliest date you can sell.
    • What to do when the originator already holds the hospital contracts in your target country.
  2. 2Match European Medicines Agency committees to the dates you promise buyers

    • Why biologics must use the centralised procedure, and how that sets the date you can promise a buyer.
    • What your team may say to a buyer once the Committee for Medicinal Products for Human Use has opined.
    • How to read the European Public Assessment Report that buyers and competitors will quote back to you.
  3. 3Apply Directive 2001/83/EC to every claim, visit and sample

    • What your team may say, and not say, before the European Commission grants the marketing authorisation.
    • Why every claim in a leaflet must match the summary of product characteristics, line by line.
    • The limits on gifts, hospitality and samples that Directive 2001/83/EC sets for visits to doctors.
  4. 4Coordinate with national competent authorities after central approval

    • Who in your company answers when a German or French authority writes after central approval.
    • Why an advertising complaint comes from a national authority and not from the European Medicines Agency.
    • How to fill the blue box on your carton so each country's labelling is ready before your first order.
  5. 5Win pricing and reimbursement from European payers country by country

    • Why authorisation by the European Commission does not set your price, and which payer sets it next.
    • Which body in France sets the price, which one assesses the product, and who to approach first.
    • How the Transparency Directive 89/105/EEC lets you demand a reasoned decision when a payer stalls.
  6. 6Clear biosimilar market access and substitution rules in each country

    • What the 2022 European statement on interchangeability lets you say to a doctor worried about switching.
    • When substitution is decided by the prescriber and when a country lets the pharmacist do it.
    • How to answer the doctor who calls your biosimilar a copy, using the comparability exercise.
  7. 7Stay inside the European Federation Code of Practice in every contact

    • Which gifts, meals and sponsorships the European Federation Code of Practice allows at a congress.
    • Why a national association code can be stricter than the European one, and where to read it.
    • How to log payments to doctors so the transfer of value is disclosed correctly the first time.
  8. 8Keep biologics in range under Good Distribution Practice across Europe

    • How to write the temperature excursion procedure a Good Distribution Practice inspector asks for first.
    • What the Qualified Person at your European importer must see in your batch file before release.
    • Why every handover between carriers, warehouses and wholesalers needs its own temperature record.
  9. 9Engage European key opinion leaders within the law and the codes

    • How to write a consultancy contract with a doctor that shows a real need before the first meeting.
    • Where scientific exchange ends and promotion begins when a medical science liaison visits a hospital.
    • What to do when a leading doctor asks for a trip, a fee or free product outside the contract.
  10. 10Draft promotional materials that European buyers and regulators accept

    • How to keep one master claim file so every country's leaflet traces back to the same source.
    • Why Germany's Heilmittelwerbegesetz, its advertising law, can stop a claim that passes elsewhere.
    • The comparison with the reference biologic that holds up in a hospital talk, and the one that fails.
  11. 11Report adverse reactions into EudraVigilance within the required deadlines

    • Why the 15-day clock for a serious reaction starts when your sales representative hears it.
    • Why every EudraVigilance report on a biologic needs the brand name and batch number.
    • What your Qualified Person for Pharmacovigilance must have ready when an inspector calls.
  12. 12Execute your European market entry strategy from filing to first sale

    • Why the marketing authorisation holder must be established in the European Economic Area.
    • How to sequence country launches by when payers decide, not by market size alone.
    • The one-page launch checklist that shows your board which approvals and procedures are still open.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Korea, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team